Based on the opposite phenotype and co-localization in the subcellular compartment between PTP1B and PTP4A1, the beneficial potential of PTP4A1 in metabolic disorders such as NAFLD might be considerable. This evidence concerns the gene PTPN1 and metabolic dysfunction-associated steatotic liver disease.